ChromaDex announces director retirement and appointment of two new independent directors

Niagen Bioscience, Inc.

Stephen Block to retire from board at 2022 annual meeting; not due to any disagreement.
Kristin Patrick appointed to board and Nominating Committee; currently EVP/CMO of Claires, Inc.
Ann Cohen appointed to board and Audit Committee; EVP/CFO of The Institute of Internal Auditors, CPA.
Each new director receives 40,000 stock option grant vesting over 3 years, plus annual retainer of $40,000.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ann Cohen

Director

NAGE · Niagen Bioscience, Inc.

Effective: 2022-04-15
Filed: April 18, 2022, 7:59 PM ET

On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.

Appointed

Kristin Patrick

Director

NAGE · Niagen Bioscience, Inc.

Effective: 2022-04-15
Filed: April 18, 2022, 7:59 PM ET

On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ann Cohen was appointed as Director at Niagen Bioscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kristin Patrick was appointed as Director at Niagen Bioscience, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-009420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.